Table A2.
Demographics and Clinical Characteristics Among US Women Age ≥ 50 Years With Ovarian Carcinoma (NAACCR Incidence, 1995 to 2008)
| Demographic or Clinical Characteristic | Women With Malignant Cancer* (N = 171,142) |
|
|---|---|---|
| No. | % | |
| Age, years | ||
| 50-59 | 45,701 | 27 |
| 60-69 | 48,250 | 28 |
| 70-79 | 47,312 | 28 |
| ≥ 80 | 29,879 | 17 |
| Race | ||
| White | 153,178 | 90 |
| Black | 11,390 | 7 |
| Other | 6,574 | 4 |
| Histologic subtype | ||
| Serous | 75,495 | 44 |
| Endometrioid | 16,518 | 10 |
| Clear cell | 6,960 | 4 |
| Mucinous | 10,503 | 6 |
| Other carcinoma | 61,666 | 36 |
| MHT use by US region | ||
| High use (West South Central) | 15,319 | 9 |
| Low use (Mid-Atlantic) | 35,250 | 21 |
Abbreviations: MHT, menopausal hormone therapy; NAACCR, North American Association of Central Cancer Registries.
*
Excluded women with borderline malignant cancer.